Prior studies found that either SU-1498, an inhibitor to VEGFR2 at endothelium, or anti-VEGF antibody to tumor cells can inhibit tumor cell adhesion to endothelium [30,33], and our results showed the same inhibition effects of SU-1498 and anti-VEGF although neither of them alter the HS of the BBB or that of MB231, suggesting that their inhibition abilities are independent of HS modulation. The gene discussed is VEGFA; the disease is neoplasm.